Revenue Breakdown
Composition ()
No data
Revenue Streams
Burning Rock Biotech Ltd (BNR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is In-hospital business, accounting for 42.1% of total sales, equivalent to CNY 62.50M. Other significant revenue streams include Pharma research and development services and Central laboratory business. Understanding this composition is critical for investors evaluating how BNR navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, Burning Rock Biotech Ltd maintains a gross margin of 75.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -12.26%, while the net margin is -12.73%. These profitability ratios, combined with a Return on Equity (ROE) of -20.25%, provide a clear picture of how effectively BNR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BNR competes directly with industry leaders such as TOI and AGL. With a market capitalization of $276.06M, it holds a significant position in the sector. When comparing efficiency, BNR's gross margin of 75.10% stands against TOI's 12.59% and AGL's -5.02%. Such benchmarking helps identify whether Burning Rock Biotech Ltd is trading at a premium or discount relative to its financial performance.
